yan feng

Dr. yan feng

Shanxi Agricultural University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2025 in Gene
Verified
Journal Article
Closed access
YFyan feng
yan feng
WGWang Guoyun
Wang Guoyun
YFYan Feng
Yan Feng
LWLin Wenji
Lin Wenji

18 April 2025 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
YFyan feng
yan feng
JJJiang Li Jin
Jiang Li Jin
JYJiao Yinming
Jiao Yinming
LWLin Wenji
Lin Wenji
FYFeng Yan
Feng Yan

11 March 2026 in npj Biofilms and Microbiomes
Verified
Journal Article
Open access
PDF file
YFyan feng
yan feng
LWLin Wenji
Lin Wenji
ZYZhao Yiji
Zhao Yiji
YFYan Feng
Yan Feng
LRLai Ren
Lai Ren
Alcoholic Heart Disease (AHD) involves gut microbiota dysbiosis, metabolic disturbances, and circadian disruption, yet their interconnections remain unclear. Using a murine AHD model, we integrated echocardiography, metabolomics, cardiac transcriptomics, and 16S rRNA sequencing to investigate alcohol-induced pathology. It evaluated dietary fiber and acetate interventions for their potential to restore gut microbiota balance, lactate homeostasis, and circadian gene expression. Statistical analyses included correlation networks, receiver operating characteristic (ROC) curves, and pathway enrichment. Chronic alcohol consumption led to gut dysbiosis characterized by an overgrowth of Akkermansia muciniphila and a depletion of Lactobacillus intestinalisand and Bacteroides acidifaciens. This condition was associated with hyperlactatemia fraction, myocardial dysfunction, evidenced by a reduced revealed fraction and cardiac fibrosis. Transcriptomic analysis revealed strong dysregulation of circadian-related genes, including BHLHE41, NFIL3, and PER2. Interventions improved microbial diversity, reduced lactate levels, and successfully regulated cardiac related indicators through the lactate-circadian rhythm pathway. ROC analysis validated BHLHE41, NFIL3, and PER2 as high-accuracy biomarkers (AUC > 0.85). Our study reveals a gut‑heart axis in AHD where microbiota‑derived lactate links to circadian disruption, worsening disease. Dietary fiber and acetate are promising therapies that rebalance metabolites and modulate circadian networks, offering novel biomarkers and strategies for alcohol‑related cardiovascular disease.

30 September 2021 in Research Square
Verified
Preprint
Open access
PDF file
YFyan feng
yan feng
RXRan Xu
Ran Xu
XLXiaohui Li
Xiaohui Li
ZDZhiwen Ding
Zhiwen Ding
YZYunzeng Zou
Yunzeng Zou
Background Myocardial hypertrophy (MH) is an independent risk factor for cardiovascular and cerebrovascular events in patients with hypertension and myocardial infarction. Recent studies have shown that PACSIN2 is associated with cardiovascular disease; however, the function of cardiomyocytes remains unclear. Here, the interaction between protein kinase C‎‎ (PKC) and PACSIN2 and the manner in which PACSIN2 regulates MH was studied. Methods The cell models were constructed with angiotensin II (AII) and PMA; qRT-PCR and Western Blot were used to verify the relative protein expression of PKC and PACSIN2; immunofluorescence was used to determine the effect of PKC upregulation on the morphology of hypertrophic cardiomyocytes after an overexpression and silencing of PACSIN2 by qRT-PCR and Western blot analysis. Results The results indicate that PKC positively regulates the expression of PACSIN2 and causes MH phenotype. The overexpression of PACSIN2 was not solely responsible for MH, while the overexpression of PACSIN2 under MH caused hypertrophy to increase. In addition, the high expression of PACSIN2 caused an increase in α-MHC mRNA, but it was not related to the expression of tubulin. The morphological results indicate that the overexpression of PKC causes MH, which causes heart failure. Conclusion Studies have shown that PACSIN2 plays an important role in maintaining myocardial cell contraction and MH. To clarify, the PAC interacting protein and the cardiomyocyte function provide a theoretical basis for the pathology and treatment of hypertrophic cardiomyopathy.